Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs CK 0801 (Primary)
- Indications Aplastic anaemia; Bone marrow disorders; Myelodysplastic syndromes; Myelofibrosis
- Focus Adverse reactions
- Sponsors Cellenkos
- 06 Nov 2019 Trial design, released in 61st Annual Meeting and Exposition of the American Society of Hematology
- 03 Jun 2019 Planned End Date changed from 1 Dec 2020 to 30 Jun 2021.
- 03 Jun 2019 Planned primary completion date changed from 1 Dec 2019 to 30 Jun 2020.